1. Home
  2. ACB vs ZNTL Comparison

ACB vs ZNTL Comparison

Compare ACB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$4.26

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$3.08

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
ZNTL
Founded
2013
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
289.0M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
ACB
ZNTL
Price
$4.26
$3.08
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
917.4K
758.5K
Earning Date
06-17-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.03
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$1.21
52 Week High
$6.67
$6.95

Technical Indicators

Market Signals
Indicator
ACB
ZNTL
Relative Strength Index (RSI) 70.06 29.12
Support Level $4.08 $2.09
Resistance Level $4.15 $3.30
Average True Range (ATR) 0.13 0.21
MACD -0.02 -0.05
Stochastic Oscillator 92.55 6.69

Price Performance

Historical Comparison
ACB
ZNTL

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: